FDA slaps gangrene warning on SGLT2 diabetes drugs by Arlene Weintraub Thursday, August 30, 2018 The FDA has raised red flags about a potentially serious flesh-eating disease in patients taking SGLT2 inhibitors.
J&J softens FDA's Invokana blow with positive kidney results by Carly Helfand Tuesday, July 17, 2018 J&J’s Invokana will have to wait longer for the FDA to decide on a key label expansion, but it's still got good news to celebrate.
ADA: AZ exec 'very optimistic' about Farxiga outcomes study by Eric Sagonowsky Wednesday, June 27, 2018 At ADA, an AstraZeneca executive said he's "very optimistic" about the company's cardiovascular outcomes study for Farxiga.
Jardiance cuts kidney disease progression in CV outcomes test by Eric Sagonowsky Monday, June 25, 2018 In a new post-hoc analysis of Jardiance's CV outcomes test, investigators found that the drug reduced kidney disease progression.
J&J's Invokana, rivals cut hospitalizations in real-world study by Eric Sagonowsky Monday, June 25, 2018 Invokana carries a warning for amputation risks, but an analysis found the drug lowered heart failure hospitalizations without increasing those risks.
AstraZeneca's Farxiga campaign plays on 'F-words' by Beth Snyder Bulik Wednesday, April 25, 2018 AstraZeneca may be the first pharma to encourage use of the “F-word.” Although in this case, AZ is talking about its diabetes drug Farxiga.
AZ touts SGLT2 benefits with latest batch of real-world data by Carly Helfand Sunday, March 11, 2018 When it comes to real-world heart benefits, SGLT2 diabetes drugs continue to impress—this time with reduced risks of heart attack and stroke.
Lilly, BI add two new Jardiance heart failure studies by Carly Helfand Wednesday, March 7, 2018 Lilly and BI are gunning for a heart-failure nod for Jardiance. And they want to be able to talk up the drug’s effects on exercise ability, too.
Busy AZ posts Q4 beats, with execs promising skid's end is near by Carly Helfand Friday, February 2, 2018 AstraZeneca needs just one more year to bring itself back to growth, CEO Pascal Soriot promised investors Friday.
J&J, Lilly and AZ diabetes meds get another real-world boost by Carly Helfand Wednesday, November 22, 2017 A new study shows SGLT2 diabetes drugs can cut the rate of major cardiovascular events in patients new to treatment.
